Ribonucleoside-diphosphate reductase subunit M2 (RRM2) could promote proliferation and chemotherapy resistance of NSCLC cells via upregulating epidermal growth factor receptor expression and AKT phosphorylation (Huang et al., 2019). Here, RRM2 is linked to non-small cell lung carcinoma.